Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: The Phase 2 DOREMY Nonrandomized Clinical Trial
Lower-dose radiation for a rare sarcoma type works just as well as standard doses while causing fewer side effects, making treatment simpler.
The DOREMY trial at long-term follow-up (median 66.4 months) shows that dose-reduced preoperative radiotherapy (36Gy vs standard 50Gy) in myxoid liposarcoma achieves excellent local control (5y LRFS 97.4%) with favorable toxicity, supporting a meaningfully simpler regimen for this rare sarcoma subtype. The authors explicitly recommend clinical adoption of this treatment reduction approach through shared decision-making, given the near-impossibility of conducting a phase 3 trial in this rare cancer.
What the study was
- Study design
- Phase 2 prospective single-group nonrandomized clinical trial (NCT02106312)
- Population
- Adults with biopsy-proven localized myxoid liposarcoma (trunk/extremity), 9 tertiary sarcoma centers in Europe and US, enrolled 2010-2020
- Sample size
- 90
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- JAMA Oncology
Why it surfaced
Phase 2 multicenter trial with long-term follow-up in a rare cancer (myxoid liposarcoma) demonstrating excellent oncological outcomes with dose reduction. Authors explicitly recommend adoption given rare disease constraints. JAMA Oncology publication with NCT registration adds credibility. High unmet need: rare disease, curative-intent treatment.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.